Seraseq® Breast CNV Mix, + 12 copies

Copy number variations (CNV) are genomic changes that lead to higher (amplification) or lower (loss) gene copies in comparison to a reference genome. Cells that are affected by aberrant copy number changes for certain cancer-associated genes may experience disruption of normal cellular function and, ultimately, tumorigenesis. Next-generation sequencing (NGS) can be used to determine CNVs across multiple genes in a sequencing run. However, without a widely adopted standard for CNV profiling, NGS assays may evaluate dosage for different targets using different wet and dry methods. In response, SeraCare has developed the first disease-specific CNV reference materials to support clinical labs performing NGS-based tumor profiling of breast cancer patient samples.

• Single sample with three clinically-relevant CNVs (save acquisition and sequencing costs)
• Develop, optimize, and validate your assay’s ability to detect a range of copy numbers (amplifications)
• CNV targets precisely quantitated with digital PCR
• Single well-characterized GM24385 human genomic DNA as background wild-type material
• Manufactured in GMP-compliant, ISO 13485-certified facilities

This specific CNV Mix for breast cancer includes 12 copies.

Solid Tumor FAQs

Review the common questions we receive from our customers and the responses we provide.

LEARN MORE